Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE 250

 880.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 913.00
  • 52 Week Low: 232.50
  • Currency: UK Pounds
  • Shares Issued: 120.78m
  • Volume: 0
  • Market Cap: £1,062.87m
  • RiskGrade: 125
  • Beta: 1.77
Select chart: 1 week | 1 month | 3 month | 1 year
 

Current

1 week

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 165.65 (25.88) (29.97)p n/a n/a n/a n/a 0.0%
31-Dec-26 225.83 0.60 (9.19)p n/a n/a n/a n/a 0.0%
31-Dec-27 291.48 30.08 14.15p 62.2 n/a n/a n/a 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue (£m)
31-Dec-2026 226 226 n/a n/a n/a 212
31-Dec-2027 292 291 n/a n/a n/a n/a
 
Earnings
31-Dec-2026 n/a n/a n/a n/a n/a n/a
31-Dec-2027 14.15p 14.04p n/a n/a n/a n/a
 
Dividend
31-Dec-2026 n/a n/a n/a n/a n/a n/a
31-Dec-2027 n/a n/a n/a n/a n/a n/a
 
Recommendations
Strong Buy 5 5 4 4 0 2
Buy 2 2 2 2 0 3
Neutral 3 3 4 4 0 5
Sell 0 0 0 0 0 0
Strong Sell 0 0 0 0 0 0
No. of Brokers 10 10 10 10 0 10
 
Average Rec 8.00 8.00 7.50 7.50 n/a 6.75

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

OXB Market Data

Currency UK Pounds
Share Price 880.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 913.00
52 Week Low 232.50
Volume 0
Shares Issued 120.78m
Market Cap £1,062.87m
Beta 1.77
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average
17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average
Price Trend
84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average
86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average
Income Not Available
Growth
5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average
24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average

What The Brokers Say

Strong Buy 5
Buy 2
Neutral 3
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page